Challenges in clinical trial design for HIV-1 cure research

The Lancet

Volumn 382, Issue 9903, 2013, Pages 1464-1465

  Eyal, Nir ^a   Kuritzkes, Daniel R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG SAFETY; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFORMED CONSENT; NOTE; PATIENT SAFETY; PRIORITY JOURNAL; REMISSION; RISK BENEFIT ANALYSIS; SEXUALITY; STUDY DESIGN; VIRUS TRANSMISSION;

EID: 84886772838     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62040-1     Document Type: Note

References (12)

1. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-98.
2. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA; March 3-6, 2013. 48LB (abstr).
3. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-85.
4. Elliott J, Solomon A, Wightman F, et al. The safety and effect of multiple doses of vorinostat on HIV transcription in HIV+ patients receiving cART. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA; March 3-6, 2013. 50LB (abstr).
5. Tolstrup M. Cyclic panobinostat (LBH 589) dosing in HIV-1 patients: fi ndings from the CLEAR trial. Towards an HIV Cure Symposium. Kuala Lumpur, Malaysia; June 30-July 3, 2013.
6. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specifi c cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
7. Worthington MG, Ross JJ. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS 2003; 17: 2145-46.
8. Cooper DA, Emery S, Cordery DV. Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment. J Infect Dis 2008; 197: 775-76.
9. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodefi ciency virus. N Engl J Med 2003; 349: 837-46.
10. El Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
11. Eyal N. Using informed consent to save trust. J Med Ethics 2012; published online Dec 8. DOI:10.1136/medethics-2012-100490.
12. Lo B, Grady C. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS 2013; 8: 2434-39.